Eisai Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eisai Company Limited with three other
companies in this sector in Japan:
Shionogi & Co Ltd
sales of 344.67 billion Japanese Yen [US$3.10 billion]
of which 100%
Taisho Pharmaceutical Holdings Co Ltd
(280.09 billion Japanese Yen [US$2.52 billion]
of which 66%
was Self-medication), and
Mitsubishi Tanabe Pharma Corp
(433.86 billion Japanese Yen [US$3.90 billion]
of which 71%
was Domestic Ethical Drug).
Eisai Company Limited reported sales of ¥600.05 billion (US$5.40 billion)
March of 2018.
increase of 11.3%
versus 2017, when the company's sales were ¥539.10 billion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Eisai Company Limited had sales
of ¥573.66 billion.
Sales of Other Business saw an increase
that was more than double the company's growth rate: sales were up
422.1% in 2018, from
¥8.97 billion to ¥46.82 billion.
Eisai Company Limited also saw significant increases in sales in
Pharmaceutical Business -Eama (up 17.1% to ¥44.30 billion)
Not all segments of Eisai Company Limited experienced an increase in sales in 2018:
sales of Pharmaceutical Business -Americans fell 2.8% to ¥113.92 billion.